Archives
-
Pioglitazone Workflows for PPARγ Inflammation Research
2026-09-29
Build reproducible Pioglitazone assays across macrophage polarization, beta-cell protection, and metabolic signaling. This workflow connects PPARγ activation with STAT-1/STAT-6 readouts while addressing solubility, dosing, controls, and cross-model interpretation.
-
RSAD2 at the Maternal-Fetal Interface in SLE
2026-09-29
Ding et al. identify RSAD2 as a pathogenic interferon-stimulated gene that connects excessive type I interferon activity with placental lipid accumulation, vascular injury, and impaired pregnancy outcomes in systemic lupus erythematosus. Human and mouse evidence places RSAD2 at the intersection of inflammatory signaling, structural-cell dysfunction, and placental vasculogenesis, while L-chicoric acid provides an initial pharmacological route for testing this mechanism.
-
Birinapant (TL32711) in Apoptosis Workflows
2026-09-28
Birinapant (TL32711) provides a practical way to interrogate IAP-dependent apoptosis, TNF signaling, and TRAIL sensitization in cancer models. This guide translates its mechanism into cell-based, combination-treatment, and xenograft workflows, with troubleshooting strategies for reproducible results.
-
FPS-ZM1: A RAGE Inhibitor Workflow for Brain Studies
2026-09-28
Use FPS-ZM1 to test whether RAGE contributes to amyloid beta uptake, neuronal stress, and neuroinflammatory readouts in brain-relevant models. A practical, controlled workflow also shows how to explore RAGE/POMC questions raised by metabolic research without treating distinct findings as interchangeable.
-
Engineering Nonomuraea to Increase A40926 Production
2026-09-27
Yan and colleagues combined targeted genetic engineering with statistical medium optimization to improve A40926 production in Nonomuraea gerenzanensis. The engineered strain and optimized M9 medium raised production through complementary interventions, highlighting the value of addressing both biosynthetic regulation and fermentation conditions.
-
DMH-1 (DMH1): ALK2 Inhibitor Evidence & Use
2026-09-26
DMH1, also written DMH-1, is an ALK2 inhibitor described as a selective probe of BMP signaling. Product information reports effects on Smad1/5/8 phosphorylation and non-small cell lung cancer models, but does not establish clinical efficacy or use in pancreatic ductal organoids.
-
DDX3 Helicase Domain Crystallization at 2.2 Å
2026-09-25
Rodamilans and Montoya established an expression and crystallization workflow for the human DDX3 helicase domain, producing crystals that diffracted to 2.2 Å. Their results provide a structural starting point for investigating DDX3, while showing that spermine tetrahydrochloride served as a crystallization additive—not as evidence about NMDA receptor activity.
-
Metabolic Control of Macrophage Antigen Presentation
2026-09-25
A mechanistic perspective on how tumor metabolism can suppress macrophage antigen presentation—and how translational teams can build mouse macrophage experiments that test this biology without confusing a useful culture reagent with proof of the tumor mechanism.
-
Safe DNA Gel Stain for DENV Assay Workflows
2026-09-24
Connect a locally oriented DENV-1 RT-LAMP research workflow with safer gel-based checks of nucleic acid products—without confusing supportive visualization with diagnostic proof. Practical staining options, blue-light imaging guidance, and troubleshooting help researchers protect downstream cloning work and interpret limitations.
-
Boc-D-FMK: Pan-Caspase Inhibitor Guide
2026-09-24
Boc-D-FMK is a cell-permeable pan-caspase inhibitor used in apoptosis research and inflammation research. Product information describes irreversible inhibition of activated caspases and reports model-specific experimental conditions; these conditions should be treated as starting points, not universal protocols.
-
Isoprinosine in Herpesvirus Egress Research
2026-09-23
Use Isoprinosine to test antiviral and immune-modulatory responses while keeping those effects distinct from the membrane-fusion step of herpesvirus nuclear egress. This workflow pairs dose and viability checks with viral-titer and cell-imaging readouts, helping researchers interpret a lower viral yield without assuming a specific molecular target.
-
Pioglitazone Workflows for PPARγ Research
2026-09-23
Build reproducible PPARγ experiments around Pioglitazone, from DMSO stock preparation and macrophage-polarization assays to DSS-induced intestinal inflammation models. The workflow connects metabolic, inflammatory, and neurodegeneration research while emphasizing controls, target engagement, and practical troubleshooting.
-
DMH1: ALK2 Inhibitor Workflows for Organoids
2026-09-22
Learn how to use DMH-1 as a selective ALK2 inhibitor for BMP-pathway experiments spanning pancreatic ductal organoids and non-small cell lung cancer research. This workflow emphasizes solvent handling, pathway-confirming readouts, migration assays, organoid optimization, and troubleshooting rather than relying on viability data alone.
-
TaCRVP Hijacks Tomato Catalase to Suppress Defense
2026-09-22
A 2026 Advanced Science study identifies TaCRVP, a cysteine-rich salivary effector from Tuta absoluta, as a regulator of tomato redox immunity. The work shows that TaCRVP both activates and stabilizes SlCAT2 catalase, suppressing hydrogen peroxide accumulation, jasmonic acid signaling, and defense metabolites that otherwise limit insect feeding.
-
hiPSC Intestinal Organoids for Pharmacokinetic Studies
2026-09-21
The 2025 reference study establishes a streamlined three-dimensional culture strategy for generating expandable human induced pluripotent stem cell-derived intestinal organoids. These organoids can be cryopreserved, maintained over time, and differentiated into intestinal epithelial cells with enterocyte CYP and transporter activities, creating a more human-relevant platform for absorption and metabolism studies.